bob4uall
3週前
First Quarter: Report is filed and investors are raising the share price.
Here's what Google's Gemini AI gleans from the report. (Gemini can make mistakes.)
Based on the provided Form 10-Q filing for Oncotelic Therapeutics, Inc. (OTLC), here is a summary of the key facts and financial indicators that could directly impact the company's share value:
1. Heavy Concentration of Assets in Joint Venture
Massive JV Valuation Dependency: A staggering 98.5% of Oncotelic's total assets ($388 million out of $393.96 million) consists solely of its 45% investment position in "GMP Bio".
Potential Pipeline vs. Accounting Reality: While an independent third-party offshore firm preliminarily estimated the potential value of the JV's drug pipeline at $2.3 billion , the filing explicitly notes this figure is non-binding, forward-looking, relies heavily on achieving milestones , and cannot be used as a current measure of fair value under U.S. GAAP.
Frozen Valuation: Oncotelic applied discounts for lack of marketability and control to determine its ASC-compliant U.S. GAAP book value. Because no material changes occurred between Dec 31, 2025, and March 31, 2026, the company recorded no new fair value adjustments for the quarter. Future share value will heavily rely on whether these clinical assets hit key valuation inflection points.
2. Clinical Pipeline & Operational Drivers
Core Product Focus: Value creation hinges on OT-101 (a TGF-$\beta$ inhibitor for difficult-to-treat cancers and COVID-19) and 5 other nanoparticle therapeutic candidates.
Upcoming Catalyst Milestones: The JV is preparing for Phase 2 and Phase 3 clinical trials for OT-101 in high-grade glioma and pancreatic cancer. Success or failure in these trials represents the primary operational risk/reward catalyst for shareholders.
Infrastructure Support: The JV owns an FDA-certified cGMP manufacturing facility in San Diego to produce its own Phase 1 clinical trial materials, mitigating some early-stage supply-chain risks.
3. Financial Health & "Burn" Indicators
Severe Cash Constancy: Oncotelic is operating with virtually no liquid capital. As of March 31, 2026, it holds only $63,614 in cash (down from $88,857 at the end of 2025) and $20,000 in restricted cash.
Surging Net Loss: The company’s quarterly net loss attributable to common shareholders expanded drastically from $298,716 in Q1 2025 to $2,193,776 in Q1 2026. This was primarily driven by a surge in General & Administrative expenses to $1.85 million.
Negative Cash Flow: Net cash used in operating activities stood at a deficit of $342,243 for the three months. The business is currently being sustained by financing activities, specifically bringing in $350,000 via convertible debt issuances during the quarter.
4. Capital Structure and Dilution Risks
Debt Overhang: The company is burdened by $14.3 million in current debt liabilities (including short-term convertible debt and related-party debt), which risks wiping out equity holders if standard repayment cannot be met.
Dilution Engine: To pay for operational expenses and services without cash, Oncotelic is actively expanding its share base. During the 3-month period, it issued 26,512 preferred shares for services (valued at $2.58 million) and over 1.6 million common shares in connection with debt.
Outstanding Share Count: As of May 14, 2026, the total outstanding common stock expanded to 444,497,302 shares. Continued reliance on equity/convertible debt to fund operations will persistently dilute existing share value.
bob4uall
2月前
The news amounts to 54 cents book-value-per-share.
As of April 14, 2026, the company reported 444,197,032 common shares outstanding. Book Value Per Share = $241,000,000 divided by 444,197,032 shares equals about $0.54 per share.
bob4uall
2月前
The latest assessment from Google Gemini AI
I'm not sure that I completely agree, in that a third-party valuation should be based on facts about asset valuation that an auditor would accept as reasonable. Will OTLC be seeking to borrow for operating funds? That's something we should find out about in further news if that is their plan.
QUESTION: How legitimate is Oncotelic (OTLC)'s claim to a $249MM net income in FY2025 today? Wouldn't the valuation of their pipeline have to be conservative?
GEMINI: The short answer is that while the $249 million net income is technically "legitimate" in terms of what Oncotelic (OTLC) filed in their April 15, 2026, Form 10-K, it is almost entirely a non-cash accounting gain.
If you're looking for cash in the bank or product sales, you won't find them here. The jump from a $4.8 million loss in 2024 to a massive profit in 2025 is driven by a specific accounting maneuver rather than operational success.
The Source of the "Profit"
The $249 million net income stems from a $365.4 million non-cash increase in the estimated fair value of Oncotelic’s 45% stake in its joint venture, GMP Biotechnology Limited (GMP Bio).
Accounting Logic: Under U.S. GAAP (specifically ASC 820), companies must report the "fair value" of certain investments. Oncotelic used an independent third-party valuation that estimated the GMP Bio pipeline at approximately $2.3 billion.
The Offset: This massive gain was partially offset by a $111.6 million deferred tax provision.
Real Revenue: The company reported $0 product revenue for FY2025.
Is the Pipeline Valuation Conservative?
You hit the nail on the head. In the biotech world, a $2.3 billion valuation for a clinical-stage pipeline (especially for an OTC-listed company with a small market cap) is aggressive, not conservative. Here is why investors should be skeptical:
Valuation vs. Realization: A third-party valuation is a mathematical model based on "probability of success" and "discounted future cash flows." It does not mean someone is willing to buy the pipeline for that price today.
Management’s Own Warning: In the filings, management explicitly states that this valuation is "non-binding" and incorporates significant discounts for "lack of control and marketability."
The Liquidity Gap: Despite the "profit," Oncotelic remains capital-constrained. Their filings indicate they have relied on funding from their own CEO and small private placements to keep the lights on. If the pipeline were truly worth $2.3 billion in a liquid market, the company likely wouldn't be struggling for small amounts of external capital.
Risk Profile: The pipeline (including OT-101 and the Deciparticle platform) is still in clinical stages. Most biotech candidates fail before reaching commercialization.
Summary for Investors
Metric Reported Value The Reality
Net Income $249 Million Paper profit; zero cash impact.
Revenue $0 No products are currently being sold.
JV Valuation $2.3 Billion Theoretical; based on future projections, not current sales.
EPS $0.59 Artificially inflated by the one-time valuation adjustment.
The Bottom Line: Oncotelic has effectively "marked to market" their own optimism. While the accounting follows the rules for reporting joint venture gains, it doesn't change the company's fundamental need for cash to actually bring these drugs to mar
bob4uall
2月前
Recent events summary by Google Gemini AI
Conversation with Gemini:
Question: Did Oncotelic (OTLC) publish any results from their March conferences in San Diego and Europe?
Gemini: Oncotelic Therapeutics (OTLC) and its subsidiary, Sapu Nano, were quite active during the March 2026 conference circuit. While they didn't release broad clinical trial results, they did publish specific data regarding their nanomedicine platforms and toxicology research.
Here are the key takeaways from those events:
San Diego: SOT 2026 Annual Meeting (March 23)
At the Society of Toxicology (SOT) meeting, Sapu Nano presented a poster titled “Everolimus Toxicology: Tissue Concentration Effects.”
The Findings: The data focused on how tissue-level exposure (rather than just blood plasma levels) relates to organ-specific toxicity for mTOR inhibitors like everolimus.
Significance: The company highlighted that these findings are foundational for their developing intravenous and nanoparticle-based formulations, which aim to improve drug delivery and reduce side effects by better controlling how the drug is distributed in the body.
Europe: BIO-Europe Spring 2026 (March 23–25)
In Basel, Switzerland, Oncotelic used the conference to formally launch its Deciparticle™ nanomedicine platform.
Pipeline Updates: They showcased their sub-20 nm drug delivery technology, designed to optimize the delivery of hydrophobic oncology drugs.
Lead Candidates: They spotlighted two specific assets:
Intravenous Everolimus: Currently in Phase 1 clinical trials.
Deciparticle-based Docetaxel: Entering Phase 1 testing.
Strategic Goal: The company emphasized its search for strategic partnerships and licensing deals to further these programs.
Recent Follow-up (April 2026)
Shortly after these conferences, Oncotelic announced a strategic partnership with TechForce Robotics on April 2, 2026. This collaboration is intended to commercialize a GMP-compliant robotics platform (PDAOAI-enhanced) to assist in their drug development and manufacturing processes.
It's worth noting that while the science is advancing, the company filed a Notification of Late Filing (NT 10-K) on March 31, indicating some administrative or financial delays in getting their annual report finalized.
bob4uall
3月前
Happening this week re OTLC in San Diego— Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
By GlobeNewswire
March 23, 2026
AGOURA HILLS, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or "Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will present new data on everolimus toxicology, focusing on tissue concentration-driven effects, at the upcoming Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo, taking place March 22-25, 2026, in San Diego, California.
The presentation will be featured during the Poster Session: ADME/Toxicokinetics I
bob4uall
3月前
"Major networking event" coming March 23-25. And, is FDA approval ahead? Will share price rally?
Google Gemini AI has retrieved the following information. Accuracy of this is unknown:
As of March 2026, Oncotelic Therapeutics (OTLC) is in a "waiting game" for clinical data to validate its massive paper valuation. While the company faces a severe liquidity crisis, there are several specific events on the horizon that could act as catalysts to move the stock toward (or past) that [Mast Hill] $0.07 conversion floor.
1. Key Clinical & Corporate Catalysts (H1 2026)- BIO-Europe Spring (March 23–25, 2026): Oncotelic is scheduled to present data on OT-101 and its Sapu-003 (intravenous everolimus) Deciparticle™ program. This is a major networking event where the company will likely be hunting for the partnership or licensing deal it needs to survive.Sapu-003 Phase 1 Enrollment: Having transitioned from preclinical to first-in-human testing in early 2026, any update on the safety or initial pharmacokinetic (PK) profile of this program could provide a boost.PDAOAI Platform Expansion: The company recently opened access to its AI "knowledge corpus." Announcements regarding new drug targets or biomarkers discovered via this AI could serve as minor technical catalysts.Joint Venture Milestone: Watch for updates regarding GMP Biotechnology (the 45%-owned JV). Any move toward an IPO for the JV or a buyout of its assets would be the most significant "macro" catalyst for OTLC.
2. The Regulatory Roadmap- The company’s path to FDA approval is focused on two primary orphan indications:Pancreatic Cancer (STOP-PC Trial): They are moving toward a Phase 2b/3 trial combining OT-101 with chemotherapy. Since previous data showed a doubling of overall survival in certain patients, the formal initiation or early enrollment updates for this pivotal trial are critical.DIPG (Pediatric Brain Cancer): OT-101 has Rare Pediatric Disease Designation. If they can move this toward a successful filing, they could receive a Priority Review Voucher (PRV), which are currently trading for $100 million+ to other pharma companies.
3. Financial Survival Analysis- The "Mast Hill" note is essentially a high-stakes bet on these catalysts.
Scenario Outcome for Stock/Debt
Positive Clinical News Stock rises >$0.07. Mast Hill converts. Debt is wiped out.
No News / "Radio Silence" Stock stays
ihubstockmover
6月前
$OTLC News! Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-ß Knowledge Corpus
AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today opened access to PDAOAI, its proprietary evidence-interrogation platform designed to extract biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models (LLMs) on proprietary data. The Company is also providing researchers access to a TGF-ß literature corpus comprising all known publications for TGF-ß- more than 125,000 PubMed abstracts- through a dedicated Discord research channel.
This platform has been developed and refined in parallel with Oncotelic’s advancing clinical and preclinical programs, materially enhancing the speed, depth, and efficiency of discovery across its pipeline.
Oncotelic invites qualified researchers, academic collaborators, and industry partners to engage directly with the PDAOAI platform and the curated TGF-ß knowledge corpus through its dedicated Discord research community. This forum provides an interactive environment for hypothesis exploration, signal interrogation, and collaborative discussion around TGF-ß–driven biology and translational opportunities. Researchers and organizations interested in partnership opportunities, data collaboration, or strategic engagement with PDAOAI are encouraged to join the community at https://discord.gg/Rj5PaHUfzw and to contact Investor Relations at ir@oncotelic.com for additional information and partnership inquiries.
Unlike many AI approaches in biomedicine that rely on fitting predictive models to a single training dataset, PDAOAI functions as an interrogation layer—structuring, embedding, clustering, and querying large bodies of scientific and clinical information so that patterns already present in the data can emerge, be tested, and be validated against known biology and real-world outcomes.
“Our philosophy is simple: let the dataset speak,” said Vuong Trieu, co-author and executive contributor. “In oncology today, the constraint is no longer data access—it is signal discovery and navigation. Over-training models on narrow datasets introduce bias and over-training models on large datasets dumb down the model due to noises. PDAOAI is built to surface reproducible, citation-backed workflows that generate testable hypotheses rather than opaque, black-box predictions.”
“PDAOAI has enabled our researchers to elevate to a level that was not possible before. It has completely changed the game and has made research both more in depth and efficient,” commented Scott Myers, Product Manager.
https://www.globenewswire.com/news-release/2025/12/22/3209178/0/en/Oncotelic-Therapeutics-Details-PDAOAI-Platform-and-Opens-Access-to-Its-Total-TGF-%CE%B2-Knowledge-Corpus.html
bob4uall
6月前
OTLC's share of assets valued at $765 million. Sounds great to me! Thanks for the article.
It's big news. I include a transcript of the video below, and everyone can see the video presentation here.
Oncotelic Therapeutics is developing treatments for hard-to-treat cancers and rare pediatric conditions. Alongside its own programs, Oncotelic also holds a 45% stake in GMP Bio, a joint venture building out a nanomedicine pipeline and advancing several late stage oncology assets. The JV just released a major update. Frost and Sullivan in Hong Kong completed an independent valuation of its pipeline at about $1.7 billion, which puts the implied value of Oncotelic's share at roughly $765 million.
Oncotelic has already kicked off an ASC compliant valuation to determine how much of that value it can eventually bring onto its balance sheet. The clinical side also shows steady momentum. OT-101 continues through a phase 3 pancreatic cancer trial and several phase 2 combination studies. GMP Bio keeps expanding its Deciparticle nanomedicine platform and its GMP licensed manufacturing facility in San Diego now supports these advancing programs. With the JV also preparing for a potential Hong Kong IPO in 2026, the valuation and ongoing clinical progress mark a strong step forward for both GMP Bio and Oncotelic. For more info, visit oncotelic.com.
ihubstockmover
6月前
$OTLC News!
Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables broad and consistent formulation of structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic peptides, linear peptides, ascomycin macrolactams, and polyketides—while maintaining a precise sub-20 nm nanoparticle profile suitable for intravenous (IV) delivery.
These findings, presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), confirm that the Deciparticle™ technology represents a chemically versatile, cGMP-ready delivery platform with the potential to support an expanding pipeline of oncology and immunology drug products.
Presentation info: PS4-04-21. Deciparticle™ Everolimus (Sapu003): From Cytostasis to Cytotoxicity via a Single mPEG Polymer and Clinic-Ready Manufacturing. Sheng-Hao Min, Kevin Forero, Johnathan Anderson, William Putnam, Can Evizi, Cassidy McCallum, Robert Hoff, Mark Ostrander, and Kwun Ho.
Deciparticle™ Platform Demonstrates Broad Formulation Capability Across Therapeutic Classes
New data from a comprehensive screening effort show that Sapu Nano’s optimized polymer reproducibly forms monodisperse nanoparticles (~15 nm) capable of encapsulating multiple classes of hydrophobic drugs:
Macrolide mTOR Inhibitors
All five clinically relevant macrolide immunosuppressants formed stable Deciparticles™:
Sirolimus
Temsirolimus
Ridaforolimus
Umirolimus
Everolimus
Differences in substitution at the C-40/C-42 or C-33 positions did not impair nanoparticle formation, highlighting the platform’s tolerance for structural diversity within the macrolide family.
Ascomycin Macrolactams
Tacrolimus formed stable sub-20 nm Deciparticles™.
Pimecrolimus, while encapsulated, produced particle sizes above the Deciparticle™ threshold—defining a steric upper bound for the platform and its suitability for optimized macrolactam design.
Cyclic and Linear Peptides
The Deciparticle™ platform successfully formulated two medically important peptide classes:
Cyclosporine A (hydrophobic cyclic peptide)
Exenatide (synthetic linear peptide)
These findings demonstrate the platform’s ability to handle both compact hydrophobic macrocycles and amphipathic linear peptides—an important expansion for peptide-based therapeutic pipelines.
Robust and Scalable cGMP Manufacturing
The platform is supported by Sapu Nano’s ISO-5 cGMP facility capable of:
One-pot bulk drug manufacturing
Sterile filtration
Automated fill/finish
Lyophilization into a stable, clinic-ready drug product
High batch reproducibility
Days to weeks post-reconstitution stability
Precision particle-size control with tight lot-to-lot consistency
This cGMP infrastructure enables fast, reliable translation from formulation to Phase 1 supply, supporting multiple INDs annually.
“With these new data, the Deciparticle™ platform has emerged as a broad, modular nanomedicine engine capable of formulating multiple classes of hydrophobic drugs that were previously constrained by solubility and delivery barriers,” said Dr. Vuong Trieu, Chief Executive Officer of Sapu Nano. “This platform advances beyond single-asset value to a multi-asset opportunity across oncology, immunology, and peptide therapeutics. Sapu003 is only the beginning.”
About the Deciparticle™ Platform
The Deciparticle™ platform is a proprietary nanotechnology engineered to encapsulate hydrophobic molecules as uniform, sub-20 nm nanoparticles for intravenous administration. The platform improves systemic exposure, reduces GI deposition, and supports precision delivery while maintaining manufacturability at clinical scale.
About Sapu Nano
Sapu Nano is a clinical-stage biotechnology company developing Deciparticle™ nanomedicine therapeutics designed to optimize the delivery of hydrophobic oncology agents and peptide-based therapeutics. The company operates an integrated ISO-5 cGMP manufacturing facility supporting rapid progression from formulation to clinical trial supply.
For more information, visit www.sapunano.com.
https://www.globenewswire.com/news-release/2025/12/02/3197836/0/en/Oncotelic-and-Sapu-Nano-Unveils-Broad-Applicability-Deciparticle-Nanomedicine-Platform-Capable-of-Formulating-Multiple-Hydrophobic-Peptide-Macrolide-and-Polyketide-Drugs.html
bob4uall
8月前
OTLC News Today:
Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
08:30 AM EDT, October 08, 2025
SYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Sapu Nano today announced the presentation of its poster, “Sapu-003: Novel Intravenous Deciparticle™ Everolimus Entering Phase 1 Study in Australia,” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). Sapu Nano is part of the Sapu family of companies, formed through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited.
Sapu-003 is the first intravenous (IV) Deciparticle™ formulation of everolimus, an mTOR inhibitor widely used in oncology. While oral everolimus (Afinitor®) has demonstrated efficacy in breast cancer, renal cell carcinoma, and neuroendocrine tumors, its broader use has been constrained by low bioavailability, variable systemic exposure, and gastrointestinal toxicities.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
EpicSage
15時間前
TrendTrade2016
5月前
メールアドレスで登録
